Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer

PURPOSE: CALGB 40601 assessed whether dual versus single human epidermal growth factor receptor 2 (HER2) –targeting drugs added to neoadjuvant chemotherapy increased pathologic complete response (pCR). Here, we report relapse-free survival (RFS), overall survival (OS), and gene expression signatures...

Full description

Saved in:
Bibliographic Details
Published in:J Clin Oncol
Main Authors: Fernandez-Martinez, Aranzazu, Krop, Ian E., Hillman, David W., Polley, Mei-Yin, Parker, Joel S., Huebner, Lucas, Hoadley, Katherine A., Shepherd, Jonathan, Tolaney, Sara, Henry, N. Lynn, Dang, Chau, Harris, Lyndsay, Berry, Donald, Hahn, Olwen, Hudis, Clifford, Winer, Eric, Partridge, Ann, Perou, Charles M., Carey, Lisa A.
Format: Artigo
Language:Inglês
Published: American Society of Clinical Oncology 2020
Subjects:
ORIGINAL REPORTS
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7723687/
https://ncbi.nlm.nih.gov/pubmed/33095682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01276
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items